A law firm has won a 39 per cent cut of a $27 million class action settlement with vehicle leasing company FleetPartners, the largest contingency fee percentage awarded to date.
The Queensland Land Court has recommended the approval of Bowen Basin Coal's Meadowbrook project to extend its Lake Vermont open cut coal mine near Dysart, over objections from environmental activists.
Artificial intelligence company Anthropic has reportedly signed its first Australian data centre lease, located in a $31.9 billion digital park in Queensland built by a Singaporean developer.
Property developer Villawood has argued that a company incorporated to manage a project in regional Victoria can't withdraw admissions over an alleged fraudulent scheme by a former director to divert management fees.
The Full Court has rejected trading platform Plus500's bid to stay a class action by investors who lost money on highly leveraged contracts for difference in light of an arbitration clause in its terms and conditions, upholding a finding that the clause was an unfair contract term.
The state of Victoria wants to declass a representative proceeding brought on behalf of climate protesters over Victoria Police's use of pepper spray, telling a judge it is prepared to negotiate individually with the 50 group members.
A class action over Medicare rebates for fertility treatments has flagged a constitutional fight in the case, saying Victoria's limitations legislation was inconsistent with federal human rights laws.
The Commonwealth has lost its bid to strike out and declass a class action on behalf of female Australian Defence Force employees who allegedly faced systemic harassment and discrimination.
A company controlled by Paul Chiodo has lobbed a $200 million suit targeting City Built director Roberto Filippini, with the former Keystone director joining the company's liquidators in chasing millions in alleged misappropriated development funds.
Pfizer has lost a patent infringement lawsuit against Samsung Bioepis over the generic version of its blockbuster autoimmune drug Enbrel, with a judge finding all but one of the patent's claims is invalid.